SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:prod.swepub.kib.ki.se:152670286"
 

Sökning: id:"swepub:oai:prod.swepub.kib.ki.se:152670286" > MDM2 inhibitors, nu...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00002786naa a2200361 4500
001oai:prod.swepub.kib.ki.se:152670286
003SwePub
008240902s2023 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1526702862 URI
024a https://doi.org/10.1038/s41598-023-31484-02 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Clavero, AL4 aut
2451 0a MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
264 c 2023-03-20
264 1b Springer Science and Business Media LLC,c 2023
520 a Activation of p53 by small molecule MDM2 inhibitors can induce cell cycle arrest or death in p53 wildtype cancer cells. However, cancer cells exposed to hypoxia can develop resistance to other small molecules, such as chemotherapies, that activate p53. Here, we evaluated whether hypoxia could render cancer cells insensitive to two MDM2 inhibitors with different potencies, nutlin-3a and navtemadlin. Inhibitor efficacy and potency were evaluated under short-term hypoxic conditions in human and mouse cancer cells expressing different p53 genotypes (wild-type, mutant, or null). Treatment of wild-type p53 cancer cells with MDM2 inhibitors reduced cell growth by > 75% in hypoxia through activation of the p53–p21 signaling pathway; no inhibitor-induced growth reduction was observed in hypoxic mutant or null p53 cells except at very high concentrations. The concentration of inhibitors needed to induce the maximal p53 response was not significantly different in hypoxia compared to normoxia. However, inhibitor efficacy varied by species and by cell line, with stronger effects at lower concentrations observed in human cell lines than in mouse cell lines grown as 2D and 3D cultures. Together, these results indicate that MDM2 inhibitors retain efficacy in hypoxia, suggesting they could be useful for targeting acutely hypoxic cancer cells.
700a Boqvist, PL4 aut
700a Ingelshed, Ku Karolinska Institutet4 aut
700a Bosdotter, Cu Karolinska Institutet4 aut
700a Sedimbi, S4 aut
700a Jiang, Lu Karolinska Institutet4 aut
700a Wermeling, Fu Karolinska Institutet4 aut
700a Vojtesek, B4 aut
700a Lane, DP4 aut
700a Kannan, Pu Karolinska Institutet4 aut
710a Karolinska Institutet4 org
773t Scientific reportsd : Springer Science and Business Media LLCg 13:1, s. 4583-q 13:1<4583-x 2045-2322
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:152670286
8564 8u https://doi.org/10.1038/s41598-023-31484-0

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy